Form 4: Cartesian Therapeutics CEO, Carsten Brunn, Reports Stock and Option Awards
SEC Form 4 Filing
Carsten Brunn, CEO of Cartesian Therapeutics, reports the acquisition of restricted stock units and employee stock options.
Summary
- Carsten Brunn, the President and CEO of Cartesian Therapeutics, reported changes in his beneficial ownership of the company's securities.
- On January 2, 2025, Brunn acquired 57,500 shares of common stock through restricted stock units (RSUs).
- These RSUs vest as to 25% on January 2, 2026, with the remainder vesting in three equal annual installments, fully vesting on January 2, 2029.
- Brunn also acquired an option to buy 169,100 shares of common stock at an exercise price of $16.93, vesting on the same schedule as the RSUs.
- Additionally, Brunn holds an option to buy 199,033 shares of common stock at an exercise price of $19.656, which vested as to 25% on January 2, 2025, with the remainder vesting in three equal annual installments.
- Following these transactions, Brunn directly owns 221,367 shares of Cartesian Therapeutics common stock.
- All amounts of securities have been adjusted to reflect a 1-for-30 reverse stock split that occurred on April 4, 2024.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options and RSUs is a common practice and generally viewed favorably as it aligns management's interests with shareholders. The vesting schedule promotes long-term commitment.
Positives
- The granting of stock options and restricted stock units to the CEO can be seen as a positive sign, aligning his interests with those of the shareholders.
- The vesting schedules encourage long-term commitment from the CEO.
Industry Context
Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.
Comparison to Industry Standards
- Executive compensation packages, including stock options and RSUs, are standard practice in the biotech industry.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize similar compensation structures to incentivize their executives.
- The vesting schedules and exercise prices are generally in line with industry norms for companies of similar size and stage of development.
Stakeholder Impact
- Shareholders: The granting of stock options and RSUs to the CEO can be viewed positively as it aligns management's interests with those of the shareholders.
- Employees: The CEO's incentivization may lead to improved company performance, benefiting employees.
- The vesting schedules encourage long-term commitment from the CEO.
Key Dates
| Date | Description |
|---|---|
| 2024/04/04 | Issuer effected a 1-for-30 reverse stock split of its common stock. |
| 2025/01/02 | Date of earliest transaction; Acquisition of restricted stock units and employee stock options. |
| 2025/01/02 | 25% of the 199,033 shares relating to the employee stock option vested. |
| 2025/01/06 | Date of signature for the Form 4 filing. |
| 2026/01/02 | 25% of the restricted stock units and 169,100 shares relating to the employee stock option will vest. |
| 2029/01/02 | Restricted stock units and 169,100 shares relating to the employee stock option will be fully vested. |
| 2034/01/01 | Expiration date for employee stock option relating to 199,033 shares. |
| 2035/01/01 | Expiration date for employee stock option relating to 169,100 shares. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.